既往感染与重复接种对台湾学童甲型H1N1pdm09流感疫苗免疫后抗体滴度的影响:公共卫生意义
本研究在台北两所小学1-6年级学童中开展前瞻性血清流行病学队列研究,评估既往感染和重复接种对甲型H1N1pdm09疫苗免疫后血凝抑制抗体滴度的影响。结果显示TIV11/12在98%儿童中诱导保护性抗体,调整疫苗效果为70.3%(95%CI:51.0-82.1%);既往感染和免疫前抗体水平正向影响免疫后抗体应答,重复接种者免疫后GMT较低但控制混杂后差异无统计学意义。
要点
- TIV11/12中甲型H1N1pdm09株在98%学童中诱导保护性抗体滴度。
- 调整疫苗效果为70.3%(95%CI:51.0-82.1%)。
- 既往感染和免疫前HI抗体水平正向影响免疫后抗体应答。
核心结论
- 研究支持在疫苗与流行株匹配良好时对学童连续三个流感季节实施甲型H1N1pdm09年度大规模接种。
- 既往感染和免疫前HI抗体水平正向影响免疫后HI抗体应答。
研究设计与样本
- 前瞻性血清流行病学队列研究,纳入台北两所小学1-6年级且有2009年以来甲型H1N1pdm09疫苗接种记录的学童。
- 在接种前、接种后1个月和4个月(T1、T2、T3)采集血清,检测抗甲型H1N1pdm09血凝抑制抗体滴度。
- 分析四种接种史:无既往接种、2009-2010季接种、2010-2011季接种、2009-2010和2010-2011连续两季接种,以及免疫前HI抗体水平对免疫后应答和调整疫苗效果的影响。
主要发现
- TIV11/12中甲型H1N1pdm09株在98%儿童中诱导保护性抗体滴度,调整疫苗效果为70.3%(95%CI:51.0-82.1%)。
- 既往未接种但感染过的儿童T2几何平均滴度为1039.7(95%CI:585.3-1845.9),未感染且未接种者为262.5(95%CI:65.9-1045),前者是后者的3.96倍(p=0.046)。
- 免疫前抗体达保护水平的既往接种儿童T2-GMT和调整疫苗效果均高于免疫前抗体未达保护水平者。
- 重复接种儿童T2-GMT低于初次接种TIV11/12者。
- 控制既往感染和T1抗体滴度后,四种接种史间T2-GMT差异无统计学意义(p=0.16)。
关键数值与推荐
- TIV11/12报告零严重不良事件。
- TIV11/12中甲型H1N1pdm09株诱导98%儿童产生保护性抗体滴度。
- 调整疫苗效果为70.3%(95%CI:51.0-82.1%)。
- 既往未接种但感染儿童T2-GMT为1039.7(95%CI:585.3-1845.9),未感染且未接种者为262.5(95%CI:65.9-1045),前者是后者的3.96倍(p=0.046)。
- 控制既往感染和T1抗体滴度后,四种接种史间T2-GMT差异p=0.16。
临床怎么用
- 研究结果支持在疫苗与流行株匹配良好时对学童实施甲型H1N1pdm09年度大规模接种,连续三个流感季节。
- 既往感染和免疫前HI抗体水平正向影响免疫后HI抗体应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study was to evaluate the effects of prior-infection and repeated vaccination on post-vaccination antibody titers. METHODS: A(H1N1)pdm09 strain was included in 2009 pandemic monovalent, 2010-2011, and 2011-2012 trivalent influenza vaccines (MIVpdm09, TIV10/11, TIV11/12) in Taiwan. During the 2011-2012 influenza season, we conducted a prospective sero-epidemiological cohort study among schoolchildren from grades 1 - 6 in the two elementary schools in Taipei with documented A(H1N1)pdm09 vaccination records since 2009. Serum samples were collected at pre-vaccination, 1-month, and 4-months post-vaccination (T1, T2, T3). Anti-A(H1N1)pdm09 hemagglutination inhibition titers (HI-Ab-titers) were examined. We also investigated the impact of four vaccination histories [(1) no previous vaccination (None), (2) vaccinated in 2009-2010 season (09v), (3) vaccinated in 2010-2011 season (10v), and (4) vaccinated consecutively in 2009-2010 and 2010-2011 seasons (09v + 10v)] and pre-vaccination HI-Ab levels on post-vaccination HI-Ab responses as well as adjusted vaccine effectiveness (aVE) against serologically-defined infection from T2 to T3. RESULTS: TIV11/12 had zero serious adverse events reported. A(H1N1)pdm09 strain in TIV11/12 elicited seroprotective Ab-titers in 98% of children and showed promising protection (aVE: 70.3% [95% confidence interval (CI): 51.0-82.1%]). Previously unvaccinated but infected children had a 3.96 times higher T2 geometric mean titer (T2-GMT) of HI-Ab than those naïve to A(H1N1)pdm09 (GMT [95% CI]: 1039.7[585.3-1845.9] vs. 262.5[65.9-1045], p = 0.046). Previously vaccinated children with seroprotective T1-Ab-titers had a higher T2-GMT and a greater aVE than those with non-seroprotective T1-Ab-titers. Repeatedly vaccinated children had lower T2-GMT than those receiving primary doses of TIV11/12. However, after controlling prior infection and T1-Ab-titers, differences in T2-GMT among the four vaccination histories became insignificant (p = 0.16). CONCLUSION: This study supports the implementation of annual mass-vaccination with A(H1N1)pdm09 in schoolchildren for three consecutive influenza seasons when vaccine and circulating strains were well matched, and found that prior infection and pre-vaccination HI-Ab levels positively impacted post-vaccination HI-Ab responses.
引用
- Liu W, Lien YH, Lee PI, et al. Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health. Vaccine. 2022. PMID: 35525727. doi:10.1016/j.vaccine.2022.03.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。